Figure 7.
Distribution of the patients. 168 D+R2 patients with either anti–IL-2 receptor antibody (n=114) or ATG (n=54) and 104 R+/ATG patients were included between January 1, 2003 and December 31, 2011, who experienced or not experienced CMV infection. Peripheral blood immunophenotyping determinations were longitudinally determined for each patient.